Compare Gilead Sciences, Inc. (GILD) vs MasterCard Inc (MA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs MasterCard Inc — how do they compare? Gilead Sciences, Inc. trades at $135.61 (market cap $163.51B), while MasterCard Inc trades at $548.5 (market cap $472.90B). The key difference: MasterCard Inc is far larger — about 2.9× Gilead Sciences, Inc.'s market cap, and Gilead Sciences, Inc. pays the higher dividend (2.49%). Which is the better fit depends on your goals.
| GILD | MA | |
|---|---|---|
Market Cap | $163.51B | $472.90B |
Sector | Health | Consumer Cyclical |
52-Week High | $155.80 | $598.96 |
52-Week Low | $108.22 | $471.55 |
Enterprise Value | $178.05B | $483.64B |
Dividend Yield | 2.49% | 0.65% |
Volume | — | 4,635,698 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
Mastercard (MA) trades at $548.26, up 1.9% today, with a bullish technical outlook and strong institutional buying. The stock shows robust fundamentals, with revenue growing from $22.2B in 2022 to $32.8B in 2025 and a net income margin of 45.88%. Recent earnings beats and a consensus price target of $634.27 reflect positive momentum, supported by aggressive AI and digital payment initiatives.
Outlook remains favorable given earnings growth and strategic positioning in digital payments, though high valuation multiples and competitive disruption from stablecoins pose risks. Wall Street sentiment is strongly bullish with 79% buy ratings, but investors should monitor execution against emerging payment technologies and macroeconomic trends affecting consumer spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About MasterCard Inc
Mastercard Incorporated provides financial transaction processing services. The Company offers payment processing services for credit and debit cards, electronic cash, automated teller machines, and travelers checks. Mastercard serves customers worldwide.
Read more on MA →
